ABSTRACT
Objective: To determine the association of serum CTX-I levels with hormone replacement and interleukin inhibi tortherapi es
Study Design: Descriptive cross sectional study Place and Duration of Study: This study was conducted at the Hayatabad Medical Complex [HMC], Peshawar from June 2012 to August 2012
Materials and Methods: A total of 100 peri-men opausal women were included in the study to determine the association of serum of CTX-I levels with hormone replacement therapy [HRT] and interleukin inhibitors
These females were randomly selected and screened for osteoporosis. The age of study population was between 45-55 years. Informed consent was taken. Detailed history was obtained regarding occupation, income, family history, number of pregnancies and medications. Women with complaints of joint pains, history of osteoarthritis, rheumatoid arthritis and any other bone disease were excluded from the study. They were radiologically assessed for osteoporosis by using Singh index as I to VI. Ethical approval for the study was taken from the Institutional Ethical Research Committee [IERC] of HMC. Blood samples were taken for estimation of hemoglobin, ESR, calcium, alkaline phosphatase and CTX-I
Results: The levels of CTX-I were elevated in peri-menopausal women who were radiographically diagnosed as osteoporotic patients. However CTX-I levels were either normal or insignificantly raised in women taking either HRT or interleukin inhibitors. The data were subjected to statistical analysis using Chi-square test on computer software SPSS-17. Results were expressed in form of tables
Association and their significance were sorted out on the software. There was a significant association of CTX-I levels with both HRT and interleukin inhibitors [p = 0.000]
Conclusion: This study revealed a significant association of serum CTX-I levels with both hormone replacement and interleukin inhibitor therapies